- Apotex has received Health Canada approval for CLOBIVIS 0.05%, indicated for the treatment of postoperative inflammation and pain following cataract surgery
- Licensed from Formosa Pharmaceuticals, CLOBIVIS uses nanoparticle technology to deliver a uniform ophthalmic suspension designed for eye care applications
- The approval further strengthens Apotex’s growing ophthalmology portfolio and supports the company’s strategy to expand access to innovative treatment options for Canadian patients
- Apotex said the launch reflects its broader “Journey of Health” strategy, with a continued focus on strategic partnerships and expanding access to specialized therapies across Canada
Takeaways:
CLOBIVIS modestly strengthens Apotex’s position in Canada’s post‑cataract segment and helps it move up the value chain in eye care beyond pure generics.
In market terms, it adds a differentiated, nanoparticle‑based steroid drop into a large, high‑volume surgery category, supporting Apotex’s broader “Journey of Health” push to grow in specialized therapies through licensing deals like its partnership with Formosa.
Source: Apotex
